Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: A randomized, multicentre, double-blind study

Blood Pressure, Supplement

Volumn 12, Issue 1, 2003, Pages 30-35

  Rosei, Enrico Agabiti ^a   Rizzoni, Damiano ^b   Comini, Silvia ^b   Boari, Gianluca ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b NONE

Author keywords

Blood pressure; Clinical trials; Hypertension; Lisinopril; Nebivolol

Indexed keywords

LISINOPRIL; NEBIVOLOL; ANTIHYPERTENSIVE AGENT; BENZOPYRAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETHANOLAMINE DERIVATIVE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SITTING; STANDING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; VERTIGO; AGED; BLOOD PRESSURE; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; TIME;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; ADRENERGIC BETA-ANTAGONISTS; TIME FACTORS;

EID: 80052746881     PISSN: 08038023     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J. Haemodynamic effects and pharmacokinetics of oral dand l-nebivolol in hypertensive patients. Eur J Clin Pharmacol 1996; 51: 259-64.
2. Gao YS, Nagao T, Bond RA. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991; 17: 964-9.
3. 2-adrenergic receptor-mediated nitric oxide production. Circulation 2000; 102: 677-82.
4. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an Larginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-71.
5. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. A randomised, double blind crossover study. Circulation 2001; 104: 511-14.
6. Andre DE, Arnet U, Yang Z, Luscher TF. Nebivolol inhibits human aortic smooth muscle cell growth: effects on cell cycle regulatory proteins. J Cardiovasc Pharmacol 2000; 35: 845-8.
7. Van Nueten L, Dupont AG, Veertommen C, Goyvaerts H, Robertson JI. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997; 11: 139-44.
8. Lacourciere Y, Lefebvre J, Poirier L. A double blind crossover comparison of nebivolol and lisinopril in treatment of ambulatory hypertension. Am J Therap 1994; 1: 74-80.
9. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
10. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs 1999; 57: 633-51.
11. Cleophas TJ, Grabowsky I, Niemeyer MG. Long-term efficacy of nebivolol monotherapy in patients with hypertension. Curr Ther Res 2001; 62: 451-61.
12. Binstock ML, Franklin KL. A comparison of compliance techniques on the control of high blood pressure. Am J Hypertens 1988; 1: 192-4S.
13. Stason WB. Opportunities to improve the cost-effectiveness of treatment for hypertension. Hypertension 1991; 18 Suppl:: I161-6.
14. Weber MA. Strategies for improving blood pressure control. Am J Hypertens 1998; 11: 897-9.
15. Van Bortel LM, Breed JG, Joosten J, Kragten JA, Lustermans FA, Mooij JM. Nebivolol in hypertension: a doubleblind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993; 21: 856-62.
16. Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomized trial. J Hum Hypertens 1997; 11: 813-19.
17. Van Nueten L, Rishoj Nielsen M, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs. enalapril in essential hypertension: a long-term double blind comparative trial. Acta Clin Belgica 1999; 54: 19-25.
18. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs. atenolol and placebo in essential hypertension: a double blind randomized trial. J Hum Hypertens 1998; 12: 135-40.
19. Fogari R, Zoppi A, Lazzari P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997; 11: 753-7.
20. Van Nueten L, Lacourciere Y, Vyssoulis G, et al. Nebivolol vs. nifedipine in the treatment of essential hypertension: a double blind, randomised, comparative trial. Am J Ther 1998; 5: 237-43.
21. Lacourciere Y, Poirier L, Lefebvre J, Provencher P, Arnott W. Comparative effects of a new cardioselective betablocker nebivolol and nifedipine sustained release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol 1992; 32: 660-6.
22. Lacourciere Y, Lefebvre J, Poirier L, Archambault F, Arnott W. Treatment of ambulatory hypertensives with nebivolol or hydrochlorotiazide alone or in combination. A randomised, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens 1994; 7: 137-45.